Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming.
Anthracyclines
Cancer
Chemotherapeutic drugs
Mechanisms of action
Resistance
Toxicity
Journal
Molecular aspects of medicine
ISSN: 1872-9452
Titre abrégé: Mol Aspects Med
Pays: England
ID NLM: 7603128
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
09
05
2023
revised:
15
07
2023
accepted:
17
07
2023
medline:
14
8
2023
pubmed:
30
7
2023
entrez:
29
7
2023
Statut:
ppublish
Résumé
Anthracyclines have been important and effective treatments against a number of cancers since their discovery. However, their use in therapy has been complicated by severe side effects and toxicity that occur during or after treatment, including cardiotoxicity. The mode of action of anthracyclines is complex, with several mechanisms proposed. It is possible that their high toxicity is due to the large set of processes involved in anthracycline action. The development of resistance is a major barrier to successful treatment when using anthracyclines. This resistance is based on a series of mechanisms that have been studied and addressed in recent years. This work provides an overview of the anthracyclines used in cancer therapy. It discusses their mechanisms of activity, toxicity, and chemoresistance, as well as the approaches used to improve their activity, decrease their toxicity, and overcome resistance.
Identifiants
pubmed: 37515939
pii: S0098-2997(23)00045-6
doi: 10.1016/j.mam.2023.101205
pii:
doi:
Substances chimiques
Anthracyclines
0
Doxorubicin
80168379AG
Antibiotics, Antineoplastic
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101205Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.